StreetInsider.com News Articles

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Wed, 13 May 2026 06:50:00 -0400

Company to host conference call and webcast today at 8:00 a.m. EDT

Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi
PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027
The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi
Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the